Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Reims – page 30

421 clinical trials in Reims, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Reims at a glance
421
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

421 trials in Reims

Open in trial search

Fallopian tube cancer+2

Not recruiting

Study on Niraparib and Dostarlimab for Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not Suitable for Platinum Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Immune thrombocytopenia

Not recruiting

Study comparing dexamethasone versus immunoglobulin plus prednisone for adults with immune thrombocytopenia (ITP) who have moderate to severe bleeding

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Assistance Publique Hopitaux De Paris

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing Volrustomig with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Hormone-refractory prostate cancer

Not recruiting

Study Comparing Radium-223 Dichloride with Abiraterone Acetate, Enzalutamide, and Prednisone in Patients with Advanced Prostate Cancer Spread to the Bone

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Bayer AG

Pustular psoriasis

Not recruiting

Study on Long-Term Spesolimab Treatment for Patients with Generalized Pustular Psoriasis from Previous Trials

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Leo Pharma A/S

Hidradenitis

Not recruiting

Study on Amlitelimab for Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Gastric cancer

Not recruiting

Study of Bemarituzumab and Chemotherapy for Patients with Advanced Stomach or Gastroesophageal Cancer with FGFR2b Overexpression

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Anal squamous cell carcinoma+4

Not recruiting

Study of pembrolizumab and vorinostat combination therapy in patients with recurrent or metastatic squamous cell carcinoma of head and neck, cervix, anus, and genital areas

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Unicancer

Hepatocellular carcinoma

Not recruiting

Study of Nivolumab for Patients with Liver Cancer at High Risk of Recurrence After Surgery or Ablation

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Idiopathic pulmonary fibrosis

Not recruiting

Study on the Effects of Bexotegrast for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bexotegrast
  • Sponsor:Pliant Therapeutics Inc.

Triple negative breast cancer

Not recruiting

Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Asthma

Not recruiting

Study on the Effects of Dexpramipexole for Adolescents and Adults with Severe Eosinophilic Asthma

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Areteia Therapeutics Inc.

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Reims

What the registry says about research in the country

01 Oncology Studies

Groundbreaking research exploring treatments for various cancers, including multiple myeloma, colorectal cancer, and esophageal squamous cell carcinoma. Studies focus on evaluating novel therapies and combination treatments to improve patient outcomes.

  • Advanced pancreatic adenocarcinoma treatments
  • Breast cancer therapies
  • Prostate cancer management

Several trials investigate immunotherapy approaches and targeted treatments for specific genetic mutations.

02 Autoimmune Conditions

Clinical trials examining innovative treatments for autoimmune disorders, with particular focus on rheumatoid arthritis and psoriatic conditions. Research aims to evaluate new therapeutic approaches and optimize existing treatments.

  • Plaque psoriasis treatments
  • Rheumatoid arthritis maintenance therapy
  • Gout management strategies

Studies emphasize long-term efficacy and safety profiles of various treatment regimens.

03 Transplant Medicine

Advanced research in kidney transplantation focusing on preventing rejection and improving long-term outcomes. Studies evaluate new immunosuppressive strategies and monitoring protocols.

  • Antibody-mediated rejection prevention
  • Novel immunosuppressive protocols
  • Post-transplant monitoring techniques

Trials aim to optimize post-transplant care and reduce rejection rates.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.